Effects of cholinesterase inhibiting sage (Salvia officinalis) on mood, anxiety and performance on a psychological stressor battery

Neuropsychopharmacology

Volumn 31, Issue 4, 2006, Pages 845-852

  Kennedy, David O ^a   Pace, Sonia ^a   Haskell, Crystal ^a   Okello, Edward J ^b   Milne, Anthea ^a   Scholey, Andrew B ^a  

^a NORTHUMBRIA UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Anxiolytic; Cognitive; Mood; Sage; Salvia officinalis; Stress

Indexed keywords

ACETYLCHOLINESTERASE; ANXIOLYTIC AGENT; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; PLACEBO; SALVIA OFFICINALIS EXTRACT;

ADULT; ALERTNESS; ANXIETY; ARTICLE; CHOLINESTERASE INHIBITION; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; ENZYME INHIBITION; FEMALE; HUMAN; IN VITRO STUDY; LOW DRUG DOSE; MALE; MENTAL PERFORMANCE; MENTAL STRESS; MOOD; NEUROPSYCHOLOGICAL TEST; NORMAL HUMAN; PLANT LEAF; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RATING SCALE; SATISFACTION; SCORING SYSTEM; SIMULATOR; SINGLE DRUG DOSE; STATE TRAIT ANXIETY INVENTORY; TASK PERFORMANCE; TRANQUILIZING ACTIVITY;

ADULT; AFFECT; ANALYSIS OF VARIANCE; ANXIETY; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MATHEMATICS; PERSONALITY INVENTORY; PSYCHOLOGICAL TESTS; PSYCHOMOTOR PERFORMANCE; SALVIA OFFICINALIS; STRESS, PSYCHOLOGICAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 33645025602     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300907     Document Type: Article

References (25)

1. Ahearn EP (1997). The use of visual analog scales in mood-disorders: a critical review. J Psychiatr Res 31: 569-579.
2. Akhondzadeh S, Noroozian N, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M (2003). Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. J Clin Pharmacy Therap 28: 1-7.
3. Bond A, Lader M (1974). The use of analogue scales in rating subjective feelings. Br J Psychol 47: 211-218.
4. Ellman GK, Courtney KD, Andres V, Featherstone RM (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7: 88-95.
5. Giacobini E (2004). Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res 50: 433-440.
6. Grutzlender J, Morris JC (2001). Cholinesterase inhibitors for Alzheimer's disease. Drugs 61: 41-52.
7. Kennedy DO, Little W, Scholey AB (2004). Attenuation of laboratory induced stress in humans following acute administration of Melissa officinalis (Lemon Balm). Psychosomatic Med 66: 607-613.
8. Kennedy DO, Scholey AB (2005). Sage and brain function. Nutr Abstracts Rev: Series A 75: 25-31.
9. Kennedy DO, Scholey AB, Tildesley NTJ, Perry EK, Wesnes KA (2002). Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (Lemon Balm). Pharmacol Biochem Behav 72: 953-964.
10. Kennedy DO, Wake G, Savelev S, Tildesley NTJ, Perry EK, Wake G et al (2003). Modulation of mood and cognitive performance following administration of single doses of Melissa officinalis (Lemon balm) with human CNS nicotinic and muscarinic receptor binding properties. Neuropsychopharmacology 28: 1871-1881.
11. Keppel G (1991). Design and Analysis. Prentice Hall: New Jersey.
12. Perry EK, Pickering AT, Wang WW, Houghton PJ, Perry NSL (1999). Medicinal plants and Alzheimer's disease: from ethnobotany to phytotherapy. J Pharmacy Pharmacol 51: 527-534.
13. Perry N, Court G, Bidet N, Court J, Perry E (1996). European herbs with cholinergic activities: potential in dementia therapy. Int J Geriatric Psychiatr 11: 1063-1069.
14. Perry NSL, Bollen C, Perry EK, Ballard C (2003). Salvia for dementia therapy: review of pharmacological activity and pilot tolerability clinical trial. Pharmacol, Biochem and Behav 75: 651-659.
15. Perry NSL, Houghton PJ, Jenner P, Keith A, Perry EK (2002). Salvia lavandulaefolia essential oil inhibits cholinesterase in vivo. Phytomedicine 9: 48-51.
16. Perry NSL, Houghton PJ, Sampson J, Theobald AE, Har S, Lis-Balchin M et al (2001). In vitro activities of S. lavandulaefolia (Spanish Sage) relevant to treatment of Alzheimer's disease. J Pharmacy Pharmacol 53: 1347-1356.
17. Perry NSL, Houghton PJ, Theobald A, Jenner P, Perry EK (2000). In vitro inhibition of human erythrocyte acetylcholinesterase by Salvia lavandulaefolia essential oil and constituent terpenes. J Pharmacy and Pharmacol 52: 895-902.
18. Savelev SU, Okello EJ, Perry EK (2004). Butyryl and Acetylcholinesterase inhibitory activities in essential oils of Salvia species and their constituents. Phytother Res 18: 315-324.
19. Savelev S, Okello E, Perry NSL, Wilkins RM, Perry E (2003). Synergistic and antagonistic interactions of anticholinesterase terpenoids in Salvia lavandulaefolia essential oil. Pharmacol Biochem Behav 75: 661-668.
20. Speilberger CD, Gorsuch RL, Lushene RE (1969). The State Trait Anxiety Inventory Manual. Consulting Psychologists Press: Palo Alto.
21. Tildesley NTJ, Kennedy DO, Perry EK, Ballard C, Savelev S, Wesnes KA et al (2003). Salvia lavandulaefolia (Spanish Sage) enhances memory in healthy young volunteers. Pharmacol Biochem Behav 75: 669-674.
22. Tildesley NTJ, Kennedy DO, Ballard CG, Wesnes KA, Hylands P, Perry EK et al. Sage improves memory and attention in healthy older volunteers: a controlled double blind acute study (submitted).
23. Tildesley NTJ, Kennedy DO, Perry EK, Ballard C, Wesnes KA, Scholey AB (2005). Cognitive and mood effects of acute administration of Salvia lavandulaefolia (Spanish Sage) to healthy young volunteers. Physiol Behav 83: 699-709.
24. Wetherell MA, Sidgreaves MC (2005). Secretory immunoglobulin - A reactivity following increases in workload intensity using the Defined Intensity Stress Simulator. Stress Health 21: 99-106.
25. Wilcock GK, Lilienfeld S, Gaens E (2000). Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International Study Group. BMJ 321: 1445-1449.